OMLYCLO
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
OMLYCLO by Celltrion is asthma, chronic rhinosinusitis with nasal polyps, and ige-mediated food allergy omalizumab products inhibit the binding of ige to the high-affinity ige receptor (fcεri) on the surface of mast cells, basophils, and dendritic cells, resulting in fcεri down-regulation on these cells. Approved for allergic reactions (type i), including anaphylaxis, more foods in adult and 4 more indications. First approved in 2025.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMLYCLO is a monoclonal antibody (omalizumab-IGEC) developed by Celltrion that works by binding to IgE to reduce allergic and asthmatic responses. It is indicated for conditions driven by IgE-mediated immune reactions. This is a biosimilar or follow-on biologic to the established anti-IgE class.
Growth
Early-stage growth asset entering a competitive market with moderate competitive pressure (30/100), suggesting medium-term commercial upside and active team building.
Mechanism of Action
Asthma, Chronic Rhinosinusitis with Nasal Polyps, and IgE-Mediated Food Allergy Omalizumab products inhibit the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and dendritic cells, resulting in FcεRI down-regulation on these cells. In allergic…
Indications (7)
Worked on OMLYCLO at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.